https://www.selleckchem.com/btk.html
Stereotactic body radiotherapy (SBRT) for oligometastases is hypothesized to improve survival and is increasingly used. Little evidence supports its safe use to treat patients with multiple metastases. To establish safety of SBRT dose schedules in patients with 3 to 4 metastases or 2 metastases in close proximity to each other. This phase 1 trial opened on August 4, 2014, and closed to accrual on March 20, 2018. Metastases to 7 anatomic locations were included bone/osseous (BO), spinal/paraspinal (SP), peripheral lung (PL), central lung (CL), abdomi
Like
Comment
Share
